Insider Insights
14.02.2024
NICE update: What manufacturers need to know about...

Our analysts explore NICE's integration of tech appraisals into treatment guidelines for to enable o...

Read more
Insider Insights
06.02.2024
Confidential rebates are raising concerns in Germa...

Proposed changes in Germany's pharma strategy suggest replacing publicly listed AMNOG rebates with c...

Read more
Insider Insights
30.01.2024
AIFA regulatory overhaul marks milestone in Pharma

AIFA's restructuring in Italy aims to streamline drug approval, replacing committees and introducing...

Read more
Insider Insights
30.01.2024
Financing of new orphan drugs in Spain increases i...

Spain seeks to enhance financing for orphan drug access, signalling a push for better timelines and ...

Read more
Insider Insights
30.01.2024
NICE recommends Talazoparib for advanced breast ca...

NICE set to endorse talazoparib for adults with BRCA 1 or 2 mutated HER2-negative locally advanced o...

Read more
Insider Insights
30.01.2024
AML treatment Tibsovo earns key rating in Germany

Tibsovo (ivosidenib) has been granted a major additional benefit rating for its use as a first-line ...

Read more
Insider Insights
30.01.2024
New MHRA procedure can accelerate patient access t...

The Medicines and Healthcare products Regulatory Agency (MHRA) in the UK has implemented the Interna...

Read more
Insider Insights
06.12.2023
New rebate percentages in the Statutory Scheme are...

The statutory scheme has been updated with new percentages for 2024-2026, and has received backlash ...

Read more
Insider Insights
04.12.2023
To improve Germany’s attractiveness, confidentia...

Germany’s Health minister has announced that publicly listed AMNOG rebates could be replaced by co...

Read more
Insider Insights
22.11.2023
AIFA reform set to move forward after receiving th...

AIFA reform is a landmark change which propels Italy towards expedited drug approvals and improved a...

Read more

Stay in the know, subscribe to our newsletter

Be the first to receive exclusive content on the latest from the pharmaceutical and market access sector.